1. Home
  2. XGN vs LEXX Comparison

XGN vs LEXX Comparison

Compare XGN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$4.26

Market Cap

71.2M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.61

Market Cap

16.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
LEXX
Founded
2002
2004
Country
United States
Canada
Employees
N/A
7
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.2M
16.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
XGN
LEXX
Price
$4.26
$0.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$8.86
$1.50
AVG Volume (30 Days)
437.7K
164.1K
Earning Date
05-11-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.12
N/A
Revenue Next Year
$13.00
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$0.46
52 Week High
$12.23
$1.55

Technical Indicators

Market Signals
Indicator
XGN
LEXX
Relative Strength Index (RSI) 66.56 38.59
Support Level $2.68 $0.56
Resistance Level $6.75 $0.85
Average True Range (ATR) 0.37 0.05
MACD 0.08 -0.00
Stochastic Oscillator 97.08 32.31

Price Performance

Historical Comparison
XGN
LEXX

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: